OLMESARTAN MEDOXOMIL 40 MG TAB
For 30 tablets
Pharmacies pay
$3.33 filed
30 × $0.11097 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$7.71 filed
30 × $0.25694 per EA, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
2.3× estimated
Medicare paid 2.3× what pharmacies pay.
Part D averages every strength and form sold under “Olmesartan Medoxomil” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$8.83 estimated
$3.33 + $0.50 (15%) + $5.00 fee per fill = $8.83
This is a model, not a price any pharmacy quoted. Shipping is not included. For a pack this cheap, the $5.00 fee is most of the estimate. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
OLMESARTAN MEDOXOMIL 40 MG TAB is how the CMS NADAC file names this product. The FDA NDC Directory lists it as olmesartan medoxomil.
FDA gives its dosage form as “tablet, film coated”, “tablet” and “tablet, coated” and its route as oral.
FDA lists 16 labelers (the companies named on the label) for its NDCs, among them Lannett Company, Inc., Accord Healthcare Inc. and Camber Pharmaceuticals, Inc.
FDA’s Established Pharmacologic Class for it is Angiotensin 2 Receptor Blocker.
The NADAC file of 2026-10-14 prices it under 31 NDCs (National Drug Codes).
NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $3.33 for 30 tablets (30 × $0.11097 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.
What NADAC measures · Why 30 tablets · NADAC explanation codes
The 16 labelers
| Labeler | NDCs | Pharmacies pay per unit |
|---|---|---|
| Novadoz Pharmaceuticals LLC | 3 | $0.11097 per EA filed |
| ScieGen Pharmaceuticals, Inc. | 3 | $0.11097 per EA filed |
| Alembic Pharmaceuticals Inc. | 2 | $0.11097 per EA filed |
| Ascend Laboratories, LLC | 2 | $0.11097 per EA filed |
| Aurobindo Pharma Limited | 2 | $0.11097 per EA filed |
| Camber Pharmaceuticals, Inc. | 2 | $0.11097 per EA filed |
| Glenmark Pharmaceuticals Inc., USA | 2 | $0.11097 per EA filed |
| HEC Pharm USA Inc. | 2 | $0.11097 per EA filed |
| Jubilant Cadista Pharmacuticals Inc. | 2 | $0.11097 per EA filed |
| Lannett Company, Inc. | 2 | $0.11097 per EA filed |
| Macleods Pharmaceuticals Limited | 2 | $0.11097 per EA filed |
| Rising Pharma Holdings, Inc. | 2 | $0.11097 per EA filed |
| Solco Healthcare US, LLC. | 2 | $0.11097 per EA filed |
| Accord Healthcare Inc. | 1 | $0.11097 per EA filed |
| Modavar Pharmaceuticals LLC | 1 | $0.11097 per EA filed |
| QUALLENT PHARMACEUTICALS HEALTH LLC | 1 | $0.11097 per EA filed |
All 31 NDCs, with labeler and price
- 00527-2427-32 · Lannett Company, Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 00527-2427-46 · Lannett Company, Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 16729-0322-15 · Accord Healthcare Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 31722-0854-30 · Camber Pharmaceuticals, Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 31722-0854-90 · Camber Pharmaceuticals, Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 33342-0180-07 · Macleods Pharmaceuticals Limited · $0.11097 per EA · eff. 2026-09-23 filed
- 33342-0180-10 · Macleods Pharmaceuticals Limited · $0.11097 per EA · eff. 2026-09-23 filed
- 43547-0301-03 · Solco Healthcare US, LLC. · $0.11097 per EA · eff. 2026-09-23 filed
- 43547-0301-09 · Solco Healthcare US, LLC. · $0.11097 per EA · eff. 2026-09-23 filed
- 50228-0341-10 · ScieGen Pharmaceuticals, Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 50228-0341-30 · ScieGen Pharmaceuticals, Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 50228-0341-90 · ScieGen Pharmaceuticals, Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 59746-0466-30 · Jubilant Cadista Pharmacuticals Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 59746-0466-90 · Jubilant Cadista Pharmacuticals Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 62332-0133-30 · Alembic Pharmaceuticals Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 62332-0133-90 · Alembic Pharmaceuticals Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 64980-0603-03 · Rising Pharma Holdings, Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 64980-0603-09 · Rising Pharma Holdings, Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 65862-0743-30 · Aurobindo Pharma Limited · $0.11097 per EA · eff. 2026-09-23 filed
- 65862-0743-90 · Aurobindo Pharma Limited · $0.11097 per EA · eff. 2026-09-23 filed
- 67877-0447-30 · Ascend Laboratories, LLC · $0.11097 per EA · eff. 2026-09-23 filed
- 67877-0447-90 · Ascend Laboratories, LLC · $0.11097 per EA · eff. 2026-09-23 filed
- 68462-0438-30 · Glenmark Pharmaceuticals Inc., USA · $0.11097 per EA · eff. 2026-09-23 filed
- 68462-0438-90 · Glenmark Pharmaceuticals Inc., USA · $0.11097 per EA · eff. 2026-09-23 filed
- 72205-0167-30 · Novadoz Pharmaceuticals LLC · $0.11097 per EA · eff. 2026-09-23 filed
- 72205-0167-66 · Novadoz Pharmaceuticals LLC · $0.11097 per EA · eff. 2026-09-23 filed
- 72205-0167-90 · Novadoz Pharmaceuticals LLC · $0.11097 per EA · eff. 2026-09-23 filed
- 72241-0080-04 · Modavar Pharmaceuticals LLC · $0.11097 per EA · eff. 2026-09-23 filed
- 72303-0850-01 · HEC Pharm USA Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 72303-0850-02 · HEC Pharm USA Inc. · $0.11097 per EA · eff. 2026-09-23 filed
- 82009-0075-90 · QUALLENT PHARMACEUTICALS HEALTH LLC · $0.11097 per EA · eff. 2026-09-23 filed
Other strengths, forms and brands
5 other products in the NADAC file share the FDA nonproprietary name olmesartan medoxomil with OLMESARTAN MEDOXOMIL 40 MG TAB.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| BENICAR 5 MG TABLET | $10.1271 per EA filed | $11.29735 per EA filed |
| BENICAR 20 MG TABLET | $12.31644 per EA filed | $11.29735 per EA filed |
| BENICAR 40 MG TABLET | $17.24162 per EA filed | $11.29735 per EA filed |
| OLMESARTAN MEDOXOMIL 5 MG TAB | $0.05748 per EA filed | $0.25694 per EA filed |
| OLMESARTAN MEDOXOMIL 20 MG TAB | $0.08049 per EA filed | $0.25694 per EA filed |
| OLMESARTAN MEDOXOMIL 40 MG TAB this page | $0.11097 per EA filed | $0.25694 per EA filed |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-07-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
Compared with its class
The middle of its 31 NDCs’ NADAC prices is $0.11097 per EA filed.
Of the 107 other products in FDA’s Angiotensin 2 Receptor Blocker class priced per EA, 91 have a higher middle NADAC price and 16 a lower one. The one in the middle is OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-12.5, at $1.15137 per EA filed (eff. 2026-09-23).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
Medicare Part D paid $7.71 for 30 tablets, at an average of $0.25694 per EA in 2024 (2024-01-01 to 2024-12-31) for “Olmesartan Medoxomil”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 3,499,458 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for OLMESARTAN MEDOXOMIL 40 MG TAB labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Olmesartan Medoxomil / Olmesartan Medoxomil: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on generic name.
Related pages
Its pharmacologic class
Related in the same class
- LOSARTAN POTASSIUM 100 MG TAB
- LOSARTAN-HYDROCHLOROTHIAZIDE 100-12.5 MG TAB
- VALSARTAN 160 MG TABLET
- ENTRESTO 24 MG-26 MG TABLET
- IRBESARTAN 150 MG TABLET